Key result
The role of beta-blockers in the management of heart failure with preserved ejection fraction remains undefined, though they may be used in the presence of comorbidities that require them.
Why the study?
Do beta-blockers improve clinical outcomes in patients with heart failure with preserved ejection fraction?
Do beta-blockers improve clinical outcomes in patients with heart failure with preserved ejection fraction?
This editorial highlights that while beta-blockers are indicated for specific comorbidities in HFpEF, their efficacy for treating HFpEF itself remains unproven and controversial.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Abdullah Al Shafi Majumder (2025) conducted an editorial in Heart failure with preserved ejection fraction (HFpEF). Beta-blockers was evaluated. The role of beta-blockers in the management of heart failure with preserved ejection fraction remains undefined, though they may be used in the presence of comorbidities that require them.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: